News & Media Catch up with our latest releases here. Filter Article 55 Podcast 3 Video 26 Article Rob Bennett 10/10/2023 Article Rob Bennett 10/10/2023 Phase Clinical Trial Results Read More Article, Video Rob Bennett 10/10/2023 Article, Video Rob Bennett 10/10/2023 Oxford Cannabinoid Technologies CEO says objective "absolutely met" in lead asset trial Read More Article Rob Bennett 09/10/2023 Article Rob Bennett 09/10/2023 OCT launches new website Read More Article Rob Bennett 28/09/2023 Article Rob Bennett 28/09/2023 CIPN explained Read More Article Rob Bennett 27/09/2023 Article Rob Bennett 27/09/2023 OCT Emerges Strong from a Pivotal Year, Nears Release of Milestone Clinical Trial Results Read More Article Rob Bennett 25/09/2023 Article Rob Bennett 25/09/2023 Final Dose Administered Read More Video, Article Rob Bennett 25/09/2023 Video, Article Rob Bennett 25/09/2023 Oxford Cannabinoid Technologies reports no adverse events in OCT461201 trial Read More Article Rob Bennett 19/09/2023 Article Rob Bennett 19/09/2023 A pharmaceutical approach to cannabinoids Read More Article Rob Bennett 05/09/2023 Article Rob Bennett 05/09/2023 Notice of AGM Read More Article Rob Bennett 31/08/2023 Article Rob Bennett 31/08/2023 2023 Final results Read More Article Rob Bennett 24/08/2023 Article Rob Bennett 24/08/2023 Cannabinoids vs Opioids Read More Article Rob Bennett 22/08/2023 Article Rob Bennett 22/08/2023 Notice of results Read More Article Rob Bennett 27/07/2023 Article Rob Bennett 27/07/2023 Oxford Cannabinoid Technologies Takes Pain Drug into Phase I; Appoints Leading Pain Expert Read More Article Rob Bennett 08/05/2023 Article Rob Bennett 08/05/2023 Valentino Parravicini Presents at the Association of Inhalation Toxicologists Annual Conference Read More Article Rob Bennett 28/04/2023 Article Rob Bennett 28/04/2023 Clinical Biomarkers & CDx Conference Europe 2023 Read More Article Rob Bennett 26/07/2022 Article Rob Bennett 26/07/2022 Oxford Cannabinoid Technologies has good opportunities in both lead products says analyst Read More Article Rob Bennett 20/06/2022 Article Rob Bennett 20/06/2022 Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address Read More Article Rob Bennett 16/05/2022 Article Rob Bennett 16/05/2022 Investor Meet Company Q&A Session Read More Article Rob Bennett 25/04/2022 Article Rob Bennett 25/04/2022 Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy Read More Article Rob Bennett 31/03/2022 Article Rob Bennett 31/03/2022 Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial Read More Newer Posts Older Posts
Article, Video Rob Bennett 10/10/2023 Article, Video Rob Bennett 10/10/2023 Oxford Cannabinoid Technologies CEO says objective "absolutely met" in lead asset trial Read More
Article Rob Bennett 27/09/2023 Article Rob Bennett 27/09/2023 OCT Emerges Strong from a Pivotal Year, Nears Release of Milestone Clinical Trial Results Read More
Video, Article Rob Bennett 25/09/2023 Video, Article Rob Bennett 25/09/2023 Oxford Cannabinoid Technologies reports no adverse events in OCT461201 trial Read More
Article Rob Bennett 19/09/2023 Article Rob Bennett 19/09/2023 A pharmaceutical approach to cannabinoids Read More
Article Rob Bennett 27/07/2023 Article Rob Bennett 27/07/2023 Oxford Cannabinoid Technologies Takes Pain Drug into Phase I; Appoints Leading Pain Expert Read More
Article Rob Bennett 08/05/2023 Article Rob Bennett 08/05/2023 Valentino Parravicini Presents at the Association of Inhalation Toxicologists Annual Conference Read More
Article Rob Bennett 28/04/2023 Article Rob Bennett 28/04/2023 Clinical Biomarkers & CDx Conference Europe 2023 Read More
Article Rob Bennett 26/07/2022 Article Rob Bennett 26/07/2022 Oxford Cannabinoid Technologies has good opportunities in both lead products says analyst Read More
Article Rob Bennett 20/06/2022 Article Rob Bennett 20/06/2022 Outsourcing in Clinical Trials UK & Ireland 2022 Conference – Dr Valentino Parravicini’s Address Read More
Article Rob Bennett 16/05/2022 Article Rob Bennett 16/05/2022 Investor Meet Company Q&A Session Read More
Article Rob Bennett 25/04/2022 Article Rob Bennett 25/04/2022 Oxford Cannabinoid Technologies Announces Formation of Scientific Advisory Board to Support Clinical Strategy Read More
Article Rob Bennett 31/03/2022 Article Rob Bennett 31/03/2022 Updates on Lead Programme 1 (OCT461201) and Programme 2 (OCT130401) - Trigeminal Neuralgia Clinical Trial Read More
